Because LLL12B showed superior in vivo PK and oral bioavailability than its parent STAT3 inhibitor LLL12, we next tested its biological activity to inhibit medulloblastoma cells in vitro and suppress medulloblastoma tumor growth in vivo. The gene discussed is STAT3; the disease is medulloblastoma.